Compare FRD & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRD | SPRO |
|---|---|---|
| Founded | 1965 | 2013 |
| Country | United States | United States |
| Employees | N/A | 25 |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.3M | 156.3M |
| IPO Year | 1995 | 2017 |
| Metric | FRD | SPRO |
|---|---|---|
| Price | $34.66 | $2.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.5K | ★ 861.4K |
| Earning Date | 06-11-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $121,157,278.00 | $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $300.00 |
| P/E Ratio | $18.07 | ★ N/A |
| Revenue Growth | ★ 55.82 | 39.24 |
| 52 Week Low | $14.52 | $1.80 |
| 52 Week High | $26.50 | $3.09 |
| Indicator | FRD | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 92.37 | 54.76 |
| Support Level | $17.90 | $2.18 |
| Resistance Level | N/A | $3.07 |
| Average True Range (ATR) | 1.36 | 0.18 |
| MACD | 0.75 | -0.02 |
| Stochastic Oscillator | 89.50 | 57.50 |
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.